
HeartBeam (BEAT) Stock Forecast & Price Target
HeartBeam (BEAT) Analyst Ratings
Bulls say
HeartBeam Inc. is well-positioned for growth as it seeks FDA clearance for its innovative telehealth products based on its patented Vector Electrocardiography (VECG) technology, which demonstrates strong equivalence to existing 12-lead systems. The company's strategic focus on capturing both premium direct-pay customers and large-scale reimbursement channels could unlock an annual revenue potential of $1.3 to $2.6 billion, supported by a projected increase in the global mobile ECG device market from $4.1 billion in 2024 to $8.9 billion by 2032. Additionally, the rising mobile healthcare devices market, estimated to grow from $155 billion in 2025 to $745.7 billion by 2035, reinforces the demand for early and remote cardiac diagnostics, suggesting strong long-term economic prospects for HeartBeam's offerings.
Bears say
HeartBeam Inc. faces significant financial risks due to the potential for inadequate or delayed reimbursement for its products, which could materially impact demand and result in negative revenue and operating results. The company's performance metrics show reduced effectiveness in "spot" mode for its ECG systems, raising concerns about the reliability of its technology in critical situations. Furthermore, the auditors’ going-concern opinion, coupled with forecasts of continued negative cash flows and potential dilution of stockholder value through new funding, underscores the substantial challenges HeartBeam could face in sustaining operations without additional capital.
This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.
HeartBeam (BEAT) Analyst Forecast & Price Prediction
Start investing in HeartBeam (BEAT)
Order type
Buy in
Order amount
Est. shares
0 shares